[vc_row][vc_column][vc_row_inner][vc_column_inner width=”1/3″ css=”.vc_custom_1559137785781{background-color: #f8dedf !important;}”][vc_column_text]
Contacts
Prof. Giuseppe Opocher
Scientific Director IOV
Project manager
e-mail: [email protected]
tel. 049 821 5644 I 7418
Dott.ssa Annarosa del Mistro
IOV Referent for WP 5
Project coordinator for the IOV-IRCCS
e-mail: [email protected]
tel. 049 821 5872
Dott.ssa Arcangela De Nicolo
IOV Referent for WP 6
[email protected]
Prof. Antonio Rosato
IOV Referent for WP 9
[email protected]
Dott. Alberto Bortolami
IOV Referent for WP 10
[email protected]
Grant office
[email protected]
tel. 049 821 5187[/vc_column_text][vc_empty_space height=”16px”][/vc_column_inner][vc_column_inner width=”2/3″][vc_column_text]In the European Union, cancer continues to represent one of the main challenges for public health. In the last 8 years, activities to combat this disease have been intensified in several respects, but some important issues remain unresolved.
The Innovative Partnership for Action Against Cancer – iPAAC, selected for funding under the Third Health Programme 2014–2020, aims to build upon the outcomes of previous EPAAC and CANCON Joint Actions. The IOV-IRCCS is among the 8 Italian institutions that collaborate with the Istituto Superiore di Sanità (one of the 24 beneficiaries of the grant agreement) through participation in the following work packages:
- WP 5: Cancer prevention
- WP 6: Genomics in cancer control and care
- WP 9: Innovative therapies in cancer
- WP 10: Governance of integrated and comprehensive cancer care
[/vc_column_text][vc_empty_space height=”1px”][vc_video link=”https://www.youtube.com/watch?v=3UHrqwAAhDw&feature=youtu.be”][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row][vc_row][vc_column][vc_single_image image=”34876″ img_size=”full” alignment=”center” onclick=”custom_link” img_link_target=”_blank” link=”https://www.interreg-central.eu/Content.Node/INTENT.html”][vc_row_inner][vc_column_inner][vc_column_text]
Objectives
The general objective of the iPAAC Joint Action (JA) is to develop innovative approaches to advances in cancer control. They include:
- advances in the field of prevention;
- global approaches to the use of genomics in cancer control;
- enhancement of information systems and cancer registers;
- improving care with a focus on major challenges;
- anticipation of the upcoming challenges in terms of innovative therapies and the management of integrated cancer control, including a new analysis of national cancer plans.
Expected results
- Support to member countries in the implementation at regional and local level of the recommendations of iPAAC and CANCON;
- strengthening of cancer prevention;
- greater effectiveness in the management of neglected tumors;
- support for the introduction of immunotherapies;
- evaluation of cancer care in member countries;
- support for legislators involved in governance;
- strengthening of information systems on a population basis.
[/vc_column_text][/vc_column_inner][/vc_row_inner][/vc_column][/vc_row]